Collaboration powers secure international data sharing through the HiFi Solves Global ConsortiumMENLO PARK, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, today announced a collaboration with DNAstack to power the world’s first global federated dataset of HiFi whole genome sequencing data. Through the HiFi Solves Global Consortium, the collaboration enables secure international research — allowing genomic insights to travel ac ...

Pacific Biosciences of California (NasdaqGS:PACB) Q4 2025 Earnings call February 12, 2026 05:00 PM ET Speaker9Good day, and welcome to PacBio's fourth quarter and full year 2025 earnings conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad, and t ...

Core Insights - PacBio reported a revenue increase of 14% year-over-year for Q4 2025, reaching $44.6 million, and a total revenue of $160.0 million for FY 2025, up from $154.0 million in FY 2024 [2][11]. Financial Performance - Q4 2025 revenue was $44.6 million, compared to $39.2 million in Q4 2024, marking a 14% increase [2]. - Consumable revenue for Q4 2025 was $21.6 million, up from $18.8 million in Q4 2024, while instrument revenue decreased to $17.3 million from $15.3 million [2]. - Gross profit for Q4 2025 was $16.6 million, compared to $10.1 million in Q4 2024, with a non-GAAP gross margin of 40% in Q4 2025 versus 31% in Q4 2024 [3][6]. - GAAP operating expenses for Q4 2025 totaled $57.8 million, significantly lower than $163.1 million in Q4 2024 [4]. - The GAAP net loss for Q4 2025 was $40.4 million, compared to a net income of $2.4 million in Q4 2024, which included a $154.4 million gain on debt restructuring [4][8]. Annual Results - For FY 2025, GAAP gross profit was $45.8 million, up from $37.3 million in FY 2024, with a non-GAAP gross margin of 40% compared to 33% in FY 2024 [6]. - GAAP operating expenses for FY 2025 were $599.6 million, compared to $511.6 million in FY 2024, while non-GAAP operating expenses decreased to $229.9 million from $289.2 million [7]. - The GAAP net loss for FY 2025 was $546.4 million, compared to a loss of $309.9 million in FY 2024 [8]. Product and Market Developments - The company placed 21 Revio systems and 42 Vega systems in Q4 2025, with a total of 61 Revio and 140 Vega systems placed for the full year [2]. - The annualized Revio pull-through per system was approximately $242,000 in Q4 2025, slightly up from $240,000 in Q4 2024 [2]. - The company highlighted record consumables revenue and growth in the clinical market, positioning itself for future growth with the upcoming launch of the SPRQ-Nx system [11]. Balance Sheet and Cash Position - As of December 31, 2025, the company had cash, cash equivalents, and investments totaling $279.5 million, down from $389.9 million a year earlier [29].

Integration of HiFi Long-Read Whole-Genome Sequencing Expands the Collective Capabilities of iHope’s Global Rare Disease NetworkMENLO PARK, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced a collaboration with iHope, a global rare disease genomics program of Genetic Alliance, to integrate PacBio’s HiFi® long-read whole-genome sequencing into iHope’s international network. iHope operates the world’s largest ...

Core Viewpoint - PacBio has completed the sale of select intellectual property and assets related to its short-read DNA sequencing technology to Illumina, Inc., receiving $48.1 million in net cash proceeds from the transaction [1][2]. Group 1: Transaction Details - The transaction involved Illumina assuming certain liabilities and granting a non-exclusive license of specific intellectual property back to PacBio [2]. - The deal was finalized on January 30, 2026 [3]. Group 2: Strategic Focus - In response to challenging macroeconomic conditions, PacBio paused the development of its high-throughput short-read sequencing platform to concentrate on its long-read sequencing innovations [3]. - The sale strengthens PacBio's balance sheet and allows the company to focus on driving the adoption of its long-read sequencing platform, particularly the accelerated development of SPRQ-Nx chemistry [3]. Group 3: Company Overview - PacBio is a leading life science technology company that designs and manufactures advanced sequencing solutions for various research applications, including human germline sequencing, oncology, and infectious disease [4].

Financial Performance & Growth - Preliminary 2025 revenue is approximately $160 million[14] - The company's cash and investments balance as of December 31, 2025, is approximately $280 million[14] - Preliminary Q4 2025 revenue is approximately $44.6 million[14] - Consumables revenue is expected to be approximately $82 million in 2025[16] - Human genomics is fueling growth in consumables, with the human market reaching approximately $48.9 million in 2025[19] Instrument Placements & Technology - Total instrument placements in 2025 reached 210[14] - Revio placements in 2025 totaled 61, with a 20% shipment growth in clinical and commercial accounts[22] - Total Revio product line shipments since launch in 2023 are approximately $334 million[24] - Vega placements in 2025 are approximately 140, representing approximately 65% of new to PacBio customers[31, 34] - Vega product line shipments in 2025 are approximately $24 million[32] Market & Clinical Adoption - The total addressable market is approximately $9 billion in 2028, expected to grow approximately 7% annually[12] - Shipments to clinically focused customers grew over 40% in 2025[38]

Core Insights - PacBio reported preliminary unaudited revenue for Q4 2025 of $44.6 million, reflecting a 14% year-over-year growth, and full-year revenue of $160.0 million, representing a 4% increase compared to 2024 [1][2] Financial Performance - Q4 2025 revenue breakdown includes: - Instrument revenue of approximately $17.3 million, up from $15.3 million in Q4 2024 - Consumable revenue of approximately $21.6 million, an increase from $18.8 million in Q4 2024 - Service and other revenue of approximately $5.7 million, compared to $5.1 million in Q4 2024 [2] - Full-year 2025 revenue breakdown includes: - Instrument revenue of approximately $53.8 million, down from $65.8 million in 2024 - Consumable revenue of approximately $81.9 million, up from $70.3 million in 2024 - Service and other revenue of approximately $24.3 million, compared to $17.9 million in 2024 [2] Product Performance - The company placed 21 Revio systems and 42 Vega systems in Q4 2025, compared to 23 and 7 placements respectively in Q4 2024 - For the full year 2025, 61 Revio systems and 140 Vega systems were placed, down from 97 and 7 placements in 2024 [2] - The annualized Revio pull-through per system was approximately $242,000 in Q4 2025, slightly up from $240,000 in Q4 2024 [2] Strategic Outlook - The CEO highlighted strong momentum from increased sales of Revio and Vega systems, along with record consumables revenue, indicating traction in clinical sequencing applications - The company aims to reduce cash burn and strengthen its financial profile, with expectations for growth driven by real-world evidence and lower costs from the SPRQ-Nx technology in 2026 and beyond [2]

Financial Performance - Total revenue for Q3 2025 was $3844 million, a decrease of 4% year-over-year (Y/Y)[12, 54] - Consumable revenue reached $213 million, showing a 15% Y/Y increase and a 12% quarter-over-quarter (Q/Q) increase[12, 36] - Instrument revenue was $113 million, a decrease of 33% Y/Y and 20% Q/Q, attributed to lower Vega shipments, especially in Europe[12, 36] - Non-GAAP gross profit was $162 million with a gross margin of 42%, compared to $130 million and 33% in Q3 2024, respectively[38] - Non-GAAP operating expenses were $539 million, lower than the $624 million in Q3 2024[38] - Non-GAAP net loss was $368 million, an improvement from the $460 million loss in Q3 2024[38] - Cash and investments stood at $2987 million as of September 30, 2025[38, 60] - The company narrows its FY 2025 revenue guidance to $155-$160 million[39] Product and Technology Updates - Revio system shipments continue, with approximately 75% going to new customers[12] - Vega system shipments also persist, with about 60% going to new customers[12] - Sequel® II CNDx received Class III Medical Device Registration approval in China[16] - SPRQ-Nx chemistry is planned for launch in 2026, aiming for a cost of less than $300 per genome at scale[27] Clinical and Research Highlights - HiFi sequencing was selected for the National Institute on Aging's Long Life Family Study, involving up to 7800 whole genomes and epigenomes[24] - HiFi sequencing was selected for the Korean Pangenome Reference Project led by KCDC, targeting over 1000 Korean genomes[26]

Core Insights - PacBio has launched an enhanced suite of PureTarget products aimed at the high-throughput carrier screening market, consolidating multiple specialized assays into a single scalable solution for inherited disease screening [1][5] Group 1: Product Features - The updated PureTarget solutions utilize PacBio's HiFi sequencing technology to address challenging genes associated with inherited conditions, allowing for a more comprehensive carrier screening approach [1][3] - The new product line includes 24- and 96-sample kit formats, designed to meet various laboratory needs and streamline workflows [3][4] - The upgraded kits can process up to 100,000 samples annually on a single Revio system, making them suitable for large-scale screening initiatives [4] Group 2: Market Context - Recent research indicates that up to 71% of individuals carry at least one pathogenic variant, underscoring the increasing relevance of carrier screening in family planning [2] - The demand for carrier screening is growing across commercial labs, health systems, and government-funded programs globally, highlighting the need for efficient and comprehensive testing solutions [2][5] Group 3: Strategic Implications - PacBio's entry into the carrier screening market reflects a commitment to simplifying complex genomic testing and expanding access to comprehensive screening worldwide [5] - The consolidation of fragmented workflows into a single test is expected to enhance operational efficiency and clinical outcomes for laboratories [5]

Core Insights - PacBio has announced a partnership with EpiCypher to integrate EpiCypher's CUTANA Hia5 enzyme into its Fiber-seq assays, enhancing the ability to study chromatin biology at single-molecule resolution [1][3] - The collaboration aims to advance research in gene regulation, particularly in the context of rare diseases and cancer, by providing a comprehensive view of genetic and epigenetic features in a single assay [2][3] Company Overview - PacBio is a leading life science technology company focused on developing advanced sequencing solutions to address complex genetic problems across various research applications, including oncology and infectious diseases [4] - The company’s HiFi long-read sequencing technology is designed to provide high-quality data for a wide range of genomic studies [4] Product Details - The CUTANA Hia5 enzyme is now commercially available in 8 and 24 reaction formats, along with a supported Fiber-seq protocol, enabling researchers to generate insights into gene regulation [3] - Fiber-seq is an advanced multi-omic whole genome sequencing assay that measures chromatin accessibility, DNA methylation, and DNA variation simultaneously, offering a more integrated approach compared to traditional methods [2][3] Research Implications - The partnership is expected to facilitate the interrogation of complex genomic regions that are difficult to analyze with short-read approaches, potentially leading to breakthroughs in understanding rare diseases [7] - By consolidating multiple assays into a single workflow, researchers can save time and resources while obtaining richer data, which is crucial for advancing biological research [7]